Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines

Investigating the cell permeability of proteolysis-targeting chimeras (PROTACs)

(2023) Hidetomo Yokoo et al.   Expert Opinion on Drug Discovery

PROTAC targeted protein degraders: the past is prologue

(2022) Miklós Békés et al.   NATURE REVIEWS DRUG DISCOVERY

Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation

(2022) Jianyu Yan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy

(2021) Peter S. Dragovich et al.   JOURNAL OF MEDICINAL CHEMISTRY

Challenges and opportunities for in vivo PROTAC delivery

(2021) Andrew B Benowitz et al.   Future Medicinal Chemistry

The PROTACtable genome

(2021) Melanie Schneider et al.   NATURE REVIEWS DRUG DISCOVERY

Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4

(2020) Marı́a Maneiro et al.   ACS Chemical Biology

PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding

(2019) Christopher P. Tinworth et al.   ACS Chemical Biology

Glycan analysis for protein therapeutics

(2019) Xiangkun Yang et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)

(2019) Peter S. Dragovich et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones

(2018) Calise Bahou et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

The pervasiveness of macropinocytosis in oncological malignancies

(2018) Cosimo Commisso   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation

(2017) Kenichiro Shimokawa et al.   ACS Medicinal Chemistry Letters

The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase

(2016) Pamela A. Haile et al.   JOURNAL OF MEDICINAL CHEMISTRY

Recent advances in the construction of antibody–drug conjugates

(2016) Vijay Chudasama et al.   Nature Chemistry

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

(2015) Jing Lu et al.   CHEMISTRY & BIOLOGY

Catalytic in vivo protein knockdown by small-molecule PROTACs

(2015) Daniel P Bondeson et al.   Nature Chemical Biology

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy

(2015) Antoine Maruani et al.   Nature Communications

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer

(2012) Thuy Vu et al.   Frontiers in Oncology

Signaling via the RIP2 Adaptor Protein in Central Nervous System-Infiltrating Dendritic Cells Promotes Inflammation and Autoimmunity

(2011) Patrick J. Shaw et al.   IMMUNITY

Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum

(2010) A. Biswas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis

(2009) H. Sato et al.   EUROPEAN RESPIRATORY JOURNAL